본문 바로가기

The longer the antithyroid drug is used, the lower the relapse rate in Graves' disease: a retrospective multicenter cohort study in Korea

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q3Scopus Q2
저널
ENDOCRINE74(1) · pp.120 · 2021
피인용
Web of Science 30Scopus 33
FWCI (Scopus)
1.61
JCR IF
JCR 2020 3.633
ISSN
1355-008X

저자

  1. Park, So Young제1저자Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  2. 김보현Division of Endocrinology and Metabolism, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
  3. 김미진Division of Endocrinology and Metabolism, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
  4. Hong, A.RamDepartment of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea
  5. Park, JunDivision of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  6. Park, HyunjuDivision of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  7. Choi, Min SunDivision of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  8. Kim, Tae HyukDivision of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  9. Kim, Sun WookDivision of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  10. Kang, Ho-Cheol교신저자Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea
  11. Chung, Jae Hoon교신저자Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

초록

Purpose Current literature suggests 12-18 months of antithyroid drug (ATD) treatment for patients with Graves' disease, but the risk of relapse is high. Although some studies reported better outcomes of long-term ATD treatment, recent data that suggest the optimal treatment duration are limited. Methods We performed a multicenter retrospective cohort study of 908 patients newly diagnosed with Graves' disease between 2006 and 2013. The relapse rate according to ATD treatment duration was analyzed. Results After initial ATD treatment, 338 patients (37.2%) had relapsed. The relapse rate according to ATD treatment duration was 42.4% at 1 year, 38.5% at 2 years, 33.8% at 3 years, 31.7% at 4 years, 30.2% at 5 years, 27.8% at 6 years, and 19.1% at more than 6 years, respectively, demonstrating a significant decreasing trend (p = 0.003). In a multivariable Cox regression analysis, ATD treatment duration was an independent risk factor for relapse (p = 0.043). Conclusions The longer that ATD therapy is used, the lower the relapse rate is in patients with Graves' disease. Long-term ATD treatment may be considered in Graves' patients who do not show complications or an economic burden from hyperthyroidism.

키워드

Grave&#8217s diseaseHyperthyroidismAntithyroid agentsTreatment outcomeRecurrence

식별자

Scopus EID
2-s2.0-85104722177
WoS UID
000640443500001